Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P070026/S129

CERAMAX CERAMIC HIP SYSTEM

Depuy Orthopaedics, Inc. · Decision date Sep 4, 2026

MEDTECHLEDGER EXPLANATIONP070026/S129

What did the FDA decide?

The FDA record for P070026/S129 describes a 30-day notice for the Ceramax Ceramic Hip System, submitted by DePuy Orthopaedics, Inc. The stated change is "the addition of an alternate component forging supplier for business continuity purposes," filed under the supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The device category is a semi-constrained hip prosthesis with metal/ceramic/ceramic/metal bearing surfaces, cemented or uncemented, product code MRA.

The identifier links this notice to the original PMA P070026; the S129 supplement is a manufacturing-supplier change, not an approval of the whole system. The record states a business-continuity purpose for adding the forging supplier. It does not identify the supplier, the component affected, or any validation data, and it supplies no evidence on safety or clinical performance. Whether the alternate forging source was accepted or how it compares to the existing source remains absent from the supplied fields.

Because the statement is limited to that purpose, the record shows regulatory filing activity only. It should not be read as a new indication, a clinical finding, or proof that the alternate-supplied components perform comparably. The supplied fields give no trial, benefit, or outcome information beyond the change description.

FDA approval order statement

the addition of an alternate component forging supplier for business continuity purposes.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Sep 4, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P070026/S129
Regulatory pathway
PMA supplement
Product code
MRA
Decision code
OK30
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, hip, semi-constrained, metal/ceramic/ceramic/metal, cemented or uncemented.

Product code
MRA
FDA device class
3

For the original device and its historical approval scope, see PMA P070026. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P070026 · Original PMA

    CERAMAX CERAMIC HIP SYSTEM

  2. P070026/S122 · Related supplement

    CERAMAX CERAMIC HIP SYSTEM

  3. P070026/S121 · Related supplement

    CERAMAX CERAMIC HIP SYSTEM

  4. P070026/S123 · Related supplement

    Ceramax Ceramic Hip System

  5. P070026/S118 · Related supplement

    Ceramax Ceramic Total Hip System

  6. P070026/S124 · Related supplement

    Ceramax Ceramic Hip System

  7. P070026/S125 · Related supplement

    Ceramax Ceramic Hip System

  8. P070026/S127 · Related supplement

    CERAMAX CERAMIC HIP SYSTEM

  9. P070026/S128 · Related supplement

    CERAMAX Ceramic Total Hip System

  10. P070026/S129 received

    Application receipt date recorded by FDA.

  11. P070026/S130 · Related supplement

    CERAMAX Ceramic Hip System

  12. P070026/S129 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P070026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070026

Product / regulatory recordCompanyPathwayDecision dateSource
Depuy Orthopaedics, Inc.PMA approvalDec 23, 2010FDA
Depuy Orthopaedics, Inc.PMA supplementAug 1, 2025FDA
Depuy Orthopaedics, Inc.PMA supplementAug 5, 2025FDA
Depuy Orthopaedics, Inc.PMA supplementDec 9, 2025FDA
Depuy Orthopaedics, Inc.PMA supplementJan 8, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementApr 10, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementApr 29, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementJun 3, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementJul 24, 2026FDA
Depuy Orthopaedics, Inc.PMA supplementAug 27, 2026FDA

Explore the linked device profile

Other records with product code MRA

Product / regulatory recordCompanyPathwayDecision dateSource
HOWMEDICA OSTEONICS CORPPMA supplementSep 17, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy Orthopaedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
700 Orthopaedic Dr., Warsaw, IN, 46582

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records